Interferon alfa-2a
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Refused (EMA) | EU (EMA) | Alpheon | — | 2006-09-05 | europa.eu ↗ |
Trials 23
Press releases naming this drug 8 releases
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 37 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Interferon alfa-2a | “the effect of interferon alfa-2a (3 megaunits three times per week for 2 years or until recurrence) on overall survival (OS) and recurrence-free survival (RFS) was compared...” PMID 14665609 ↗ Dec 200326“Arm II (recombinant interferon alfa-2a): Patients receive recombinant interferon alfa-2a subcutaneously (SC) 3 times weekly for 12 weeks.” NCT00416429 ↗ “combination treatment with 13-cis-retinoic acid (13-CRA) plus interferon alfa-2a (IFN-alpha-2a) was superior to IFN-alpha-2a alone” PMID 15961764 ↗ Jun 2005 “1.2.1 Interferon Alfa 2a Interferon Alfa was the first drug shown to have bioactivity against HCV.” NCT00502970 ↗ “interferon alfa-2a (IFN-alpha-2a) in patients with untreated, advanced renal cancer.” PMID 19171708 ↗ Jan 2009 |
| Known as | Human Serum ALbumin/interferon alpha2a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01997944 ↗ |
| Known as | IFN | “IFN (Interferon, Peg-interferon alpha-2a or PEGASYS®) is available as a sterile, preservative-free, colorless to light yellow injectable solution administered subcutaneously.” NCT02340962 ↗1“bevacizumab, interferon alfa-2a (IFN)” NCT00719264 ↗ |
| Known as | IFN alfa-2a | “To determine the safety and efficacy of two doses of interferon alfa-2a ( IFN alfa-2a ) in combination with zidovudine ( AZT )/zalcitabine ( ddC ) versus AZT/ddC only in...” NCT00000754 ↗ |
| Known as | IFN α2a | “This study compares the long-term efficacy and safety of interferon (IFN) α2a and cyclosporine (cyclosporin A, CsA) following suppression of acute attack by high-dose oral...” NCT03209219 ↗ |
| Known as | IFN-A2A | “To evaluate the anti-HIV effect of single agent versus combination therapy with zidovudine (AZT) and interferon alfa-2a (IFN-A2a), as measured by p24 protein expression, viral...” NCT00000696 ↗3“To determine the safety and effectiveness of combining zidovudine (AZT) and interferon alfa-2a (IFN-A2a) in a treatment for Kaposi's sarcoma (KS) in patients who have AIDS.” NCT00000687 ↗ “The two kinds are interferon alpha (IFN-A) and interferon alpha-2A (recombinant) (IFN-A2A).” NCT00001113 ↗ “The two kinds are interferon alpha (IFN-A) and interferon alpha-2A (recombinant) (IFN-A2A).” NCT00000725 ↗ |
| Known as | IFN-alpha-2a | “combination treatment with 13-cis-retinoic acid (13-CRA) plus interferon alfa-2a (IFN-alpha-2a) was superior to IFN-alpha-2a alone” PMID 15961764 ↗ Jun 20051“interferon alfa-2a (IFN-alpha-2a) in patients with untreated, advanced renal cancer.” PMID 19171708 ↗ Jan 2009 |
| Known as | IFNα | “Interferon alpha (IFNα) s.c., may work as a low toxic preconditioning regimens” NCT04072263 ↗ |
| Known as | Interferon | “IFN (Interferon, Peg-interferon alpha-2a or PEGASYS®) is available as a sterile, preservative-free, colorless to light yellow injectable solution administered subcutaneously.” NCT02340962 ↗ |
| Known as | interferon alpha-2A (recombinant) | “The two kinds are interferon alpha (IFN-A) and interferon alpha-2A (recombinant) (IFN-A2A).” NCT00000725 ↗ |
| Known as | Interferon alpha2 a | “We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period.” NCT00508040 ↗8“interferon-alpha-2a (1), 9 MU given subcutaneously three times per week, once per week for 6 weeks.” PMID 12074329 ↗ May 2002 |
| Known as | Peg-interferon alpha-2a | “IFN (Interferon, Peg-interferon alpha-2a or PEGASYS®) is available as a sterile, preservative-free, colorless to light yellow injectable solution administered subcutaneously.” NCT02340962 ↗ |
| Known as | PEGASYS | “IFN (Interferon, Peg-interferon alpha-2a or PEGASYS®) is available as a sterile, preservative-free, colorless to light yellow injectable solution administered subcutaneously.” NCT02340962 ↗1“PEG-IFN-α2a) (PegasysTM, Roche Pharma Schweiz AG, Reinach, Switzerland) 180 μg QW” NCT00433069 ↗ |
| Known as | Roferon | “Interferon alfa 2a [Roferon]” NCT00738530 ↗ |
| Known as | Roferon-A | “The purpose of this study is to determine whether combination therapy with bevacizumab (Avastin), dacarbazine and interferon-alfa-2a (Roferon-A) is effective in patients with...” NCT00308607 ↗ |
| Action | Inhibit | “IFN alfa-2a inhibits translation of viral proteins.” NCT00000754 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Alpha-2A Interferon” NCT00000687 ↗ |
| Route | Subcutaneous | “IFN-A2a is administered as a single subcutaneous injection once a day.” NCT00000687 ↗ |